Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
Open Access
- 24 March 2015
- journal article
- consensus statement
- Published by Springer Science and Business Media LLC in Nature Reviews Urology
- Vol. 12 (4), 225-235
- https://doi.org/10.1038/nrurol.2015.58
Abstract
No abstract availableKeywords
This publication has 118 references indexed in Scilit:
- Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of MaintenanceEuropean Urology, 2013
- Intravesical chemotherapy plus bacille Calmette‐Guérin in non‐muscle invasive bladder cancer: a systematic review with meta‐analysisBJU International, 2012
- Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathwayUrologic Oncology, 2012
- Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective TrialJournal of Urology, 2012
- Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)European Urology, 2011
- Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancerBJU International, 2010
- Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, 2010
- Maintenance intravesical bacillus Calmette‐Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study GroupInternational Journal of Urology, 2010
- Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the BladderEuropean Urology, 2010
- Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic StudyEuropean Urology, 2010